ARL6IP5 in cancers: bidirectional function and therapeutic value
Zenan Hu, Hanxun Yue, Liang Qiao
TL;DR
This paper reviews the role of ARL6IP5 in cancers, highlighting its mixed effects and potential for cancer therapy.
Contribution
The paper provides a summary of ARL6IP5's bidirectional role in cancer progression and its therapeutic potential.
Findings
ARL6IP5 has both tumor-promoting and tumor-suppressing roles in different cancers.
It plays a significant role in chronic hepatitis virus-related hepatocellular carcinoma progression.
ARL6IP5 shows potential as a target for cancer therapy.
Abstract
ARL6IP5 (ADP-ribosylation-like factor 6 interacting protein 5) plays an important role in a variety of physiological or pathological processes, including in cancers. However, the biological roles of ARL6IP5 in cancers are controversial. In this mini-review, we summarized the current understanding on the role of ARL6IP5 in cancers, particularly in the progression of chronic hepatitis virus-related hepatocellular carcinoma, as well as the potential values of ARL6IP5 in cancer therapy.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinoids in leukemia and cellular processes · RNA regulation and disease · Adenosine and Purinergic Signaling